Plano East Gong Aff
| Tournament | Round | Opponent | Judge | Cites | Round Report | Open Source | Edit/Delete |
|---|---|---|---|---|---|---|---|
| Loyola | 1 | Bellerina Hu | Truman Le |
|
|
| |
| x | 1 | x | x |
|
|
| Tournament | Round | Report |
|---|---|---|
| Loyola | 1 | Opponent: Bellerina Hu | Judge: Truman Le 1ac- evergreening |
To modify or delete round reports, edit the associated round.
Cites
| Entry | Date |
|---|---|
ContactTournament: x | Round: 1 | Opponent: x | Judge: x | 9/4/21 |
SO--1AC--EvergreeningTournament: Loyola | Round: 1 | Opponent: Bellerina Hu | Judge: Truman Le 1AC: InnovationThe Advantage is Innovation1~ We are in an innovation crisis – new drugs are not being developed in favor of re-purposing old drugs to infinitely extend patent expiration.Feldman 1 Robin Feldman 2-11-2019 "'One-and-done' for new drugs could cut patent thickets and boost generic competition" https://www.statnews.com/2019/02/11/drug-patent-protection-one-done/ (Arthur J. Goldberg Distinguished Professor of Law, Albert Abramson '54 Distinguished Professor of Law Chair, and Director of the Center for Innovation)SidK + Elmer 2~ We control Uniqueness – up to 80 of all new patents are not new drugs but old ones.Feldman 2 Robin Feldman 18, May your drug price be evergreen, Journal of Law and the Biosciences, Volume 5, Issue 3, December 2018, Pages 590–647, https://doi.org/10.1093/jlb/lsy022 Arthur J. Goldberg Distinguished Professor of Law, Albert Abramson '54 Distinguished Professor of Law Chair, and Director of the Center for Innovation (Study Notes: Presenting the first comprehensive study of evergreening, this article examines the extent to which evergreening behavior—which can be defined as artificially extending the protection cliff—may contribute to the problem. The author analyses all drugs on the market between 2005 and 2015, combing through 60,000 data points to examine every instance in which a company added a new patent or exclusivity.)sid 3~ The only major study confirms our Internal Link – Evergreening decimates competition by resulting in functional monopoliesArnold Ventures 20 9-24-2020 "'Evergreening' Stunts Competition, Costs Consumers and Taxpayers" https://www.arnoldventures.org/stories/evergreening-stunts-competition-costs-consumers-and-taxpayers/ (Arnold Ventures is focused on evidence-based giving in a wide range of categories including: criminal justice, education, health care, and public finance)Elmer 4~ Reject Negative Turns – they're pharmaceutical lies – the Plan isn't anti-Patent, just pro-innovation – breaking down secondary patents is key.Radhakrishnan 16 Priti Radhakrishnan 6-14-2016 "Pharma's secret weapon to keep drug prices high" https://www.statnews.com/2016/06/14/secondary-patent-gilead-sovaldi-harvoni/ (Priti Radhakrishnan is cofounder and director of the Initiative for Medicines, Access and Knowledge (I-MAK), a US-based nonprofit group of scientists and lawyers working globally to get people lifesaving medicines. Before founding I-MAK, she worked as a health attorney in the US, Switzerland, and India.)Elmer 3 impacts:1~ Only innovation now solves AMR super-bugs — timeframe's key.Sobti 19 ~Dr. Navjot Kaur Sobti is an internal medicine resident physician at Dartmouth-Hitchcock-Medical Center/Dartmouth School of Medicine and a member of the ABC News Medical Unit. May 1, 2019. "Amid superbug crisis, scientists urge innovation". https://abcnews.go.com/Health/amidst-superbug-crisis-scientists-urge-innovation/story?id=62763415~~ Dhruv Evolving superbugs trigger extinction.Srivatsa '17 (Kadiyali; specialist in pediatric intensive and critical care medicine in the UK. Invented the bacterial identification tool 'MAYA'; 1-12-2017; "Superbug Pandemics and How to Prevent Them", American Interest; https://www.the-american-interest.com/2017/01/12/superbug-pandemics-and-how-to-prevent-them/, Accessed: 8-31-2021; AU) 2~ Pharma spills-over – has cascading global impacts that are necessary for human survival.NAS 8 National Academy of Sciences 12-3-2008 "The Role of the Life Sciences in Transforming America's Future Summary of a Workshop" Re-cut by Elmer Climate change destroys the world.Specktor 19 ~Brandon writes about the science of everyday life for Live Science, and previously for Reader's Digest magazine, where he served as an editor for five years~ 6-4-2019, "Human Civilization Will Crumble by 2050 If We Don't Stop Climate Change Now, New Paper Claims," livescience, https://www.livescience.com/65633-climate-change-dooms-humans-by-2050.html JW 3~ Expanding breadth of Pharma Innovation into neglected diseases results in global linkages that revitalizes global health diplomacy.Hotez 16, Peter J. Blue marble health: an innovative plan to fight diseases of the poor amid wealth. JHU Press, 2016. (Sabin Vaccine Institute and Texas Children's Hospital Center for Vaccine Development, Departments of Pediatrics and Molecular Virology and Microbiology)Elmer Solves hotspot escalationNang and Martin 17, Roberto N., and Keith Martin. "Global health diplomacy: A new strategic defense pillar." Military medicine 182.1-2 (2017): 1456-1460. (MC, Global Health Division, Uniformed Services University of the Health Sciences)Elmer 1AC: PlanPlan – The member nations of the World Trade Organization ought to reduce intellectual property protections for medicines by implementing a one-and-done approach for patent protection.The Plan solves Evergreening.Feldman 3 Robin Feldman 2-11-2019 "'One-and-done' for new drugs could cut patent thickets and boost generic competition" https://www.statnews.com/2019/02/11/drug-patent-protection-one-done/ (Arthur J. Goldberg Distinguished Professor of Law, Albert Abramson '54 Distinguished Professor of Law Chair, and Director of the Center for Innovation)SidK + Elmer Reforming the Patent Process would lower Drug Prices and incentivize Pharma Innovation by revitalizing the Market.Stanbrook 13, Matthew B. "Limiting "evergreening" for a better balance of drug innovation incentives." (2013): 939-939. (MD (University of Toronto) PhD (University of Toronto))Elmer Only reinvigorating innovation solves high drug prices — topples drug monopolies.Engelberg 19 ~Alfred B. Engelberg is a retired intellectual property lawyer and philanthropist. During his legal career, he was a patent examiner at the US Patent Office, a patent trial attorney at the US Department of Justice, and a member of the New York City law firm of Amster, Rothstein, and Engelberg. February 28, 2019. "A Shortfall In Innovation Is The Cause Of High Drug Prices". https://www.healthaffairs.org/do/10.1377/hblog20190228.636555/full/~~ Dhruv | 9/4/21 |
Open Source
| Filename | Date | Uploaded By | Delete |
|---|---|---|---|
9/4/21 | nathangong318109@gmailcom |
|